Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Gene Therapeutics & RNAi

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1787190

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1787190

mRNA Therapeutics

PUBLISHED:
PAGES: 282 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5850
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global mRNA Therapeutics Market to Reach US$34.5 Billion by 2030

The global market for mRNA Therapeutics estimated at US$13.3 Billion in the year 2024, is expected to reach US$34.5 Billion by 2030, growing at a CAGR of 17.1% over the analysis period 2024-2030. Prophylactic Products, one of the segments analyzed in the report, is expected to record a 18.3% CAGR and reach US$25.6 Billion by the end of the analysis period. Growth in the Therapeutic Products segment is estimated at 14.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.6 Billion While China is Forecast to Grow at 22.8% CAGR

The mRNA Therapeutics market in the U.S. is estimated at US$3.6 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$7.7 Billion by the year 2030 trailing a CAGR of 22.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 12.6% and 15.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 13.7% CAGR.

Global mRNA Therapeutics Market - Key Trends & Drivers Summarized

How Are mRNA Therapeutics Revolutionizing Drug Development and Disease Treatment?

The rise of mRNA therapeutics has fundamentally changed the landscape of drug development, offering a powerful platform for treating a wide range of diseases, from infectious diseases and cancer to genetic disorders and rare conditions. Unlike traditional biologics, which require complex production processes and cell culture systems, mRNA-based therapies leverage synthetic messenger RNA to instruct cells to produce therapeutic proteins directly within the body. This approach significantly accelerates drug development timelines and enhances precision in targeting disease pathways. The groundbreaking success of mRNA COVID-19 vaccines demonstrated the speed and flexibility of this technology, leading to a surge in research efforts aimed at expanding mRNA applications beyond vaccines. The ability to encode virtually any protein into an mRNA sequence has positioned this technology as a promising tool for personalized medicine, where treatments can be tailored to an individual’s genetic profile. Additionally, advancements in lipid nanoparticle (LNP) delivery systems have improved the stability and targeted delivery of mRNA therapeutics, addressing previous challenges related to degradation and immunogenicity. As pharmaceutical companies and research institutions continue to invest in mRNA-based solutions, the potential for treating conditions such as autoimmune diseases, cardiovascular disorders, and neurodegenerative conditions is rapidly expanding, making mRNA therapeutics one of the most dynamic areas in modern biotechnology.

What Technological Advancements Are Enhancing the Efficacy and Delivery of mRNA Drugs?

The rapid evolution of mRNA therapeutics is largely driven by advancements in formulation, delivery technologies, and sequence optimization. One of the most significant breakthroughs has been the development of chemically modified nucleotides, such as N1-methylpseudouridine, which enhance mRNA stability and reduce unwanted immune responses. Improved in vitro transcription (IVT) processes have increased mRNA yield and purity, reducing the presence of double-stranded RNA contaminants that can trigger inflammatory responses. The refinement of lipid nanoparticle (LNP) carriers has also played a crucial role in improving mRNA delivery, ensuring that the therapeutic payload reaches target tissues with high efficiency while minimizing off-target effects. Researchers are now exploring next-generation delivery systems, including polymer-based nanoparticles, exosome-derived vesicles, and peptide-based formulations, to further enhance tissue specificity and prolonged therapeutic effects. Additionally, the emergence of self-amplifying mRNA (saRNA) has opened new possibilities for lower-dose, longer-lasting treatments by enabling the production of therapeutic proteins at reduced mRNA concentrations. As artificial intelligence (AI) and machine learning are integrated into drug discovery, predictive modeling is being used to optimize mRNA sequences and delivery strategies, accelerating the development of novel mRNA-based therapies. These technological advancements are expected to expand the scope of mRNA therapeutics, unlocking new treatment paradigms across multiple disease areas.

How Are Regulatory and Manufacturing Challenges Impacting the mRNA Therapeutics Market?

Despite the immense potential of mRNA therapeutics, the industry faces regulatory and manufacturing challenges that must be addressed to enable widespread adoption. The highly specialized nature of mRNA production requires stringent quality control measures, particularly in raw material sourcing, in vitro transcription, and purification processes. Regulatory agencies such as the FDA and EMA have introduced new guidelines for mRNA therapeutics, focusing on product stability, immunogenicity, and manufacturing scalability. The need for Good Manufacturing Practice (GMP)-compliant production facilities has increased demand for contract development and manufacturing organizations (CDMOs) that specialize in mRNA drug production. However, the global supply chain for key components such as nucleotides, capping reagents, and lipid carriers remains vulnerable to disruptions, posing risks to large-scale manufacturing. Additionally, regulatory frameworks are still evolving for personalized mRNA therapies, such as cancer vaccines, which require customized formulations for individual patients. Another key challenge is the cost of production, as mRNA-based drugs often require cold-chain storage and sophisticated logistics for global distribution. Addressing these challenges will require continued collaboration between biotech companies, regulatory agencies, and manufacturing partners to ensure that mRNA therapeutics can be developed and distributed efficiently and safely on a global scale.

What Are the Key Growth Drivers Propelling the mRNA Therapeutics Market?

The growth in the mRNA therapeutics market is driven by several factors, including increasing investments in biotechnology research, expanding applications beyond vaccines, and technological advancements in mRNA delivery systems. The success of mRNA-based COVID-19 vaccines has significantly boosted funding for mRNA research, leading to an influx of clinical trials investigating mRNA therapies for cancer, metabolic diseases, and infectious diseases such as influenza, HIV, and Zika virus. The rise of personalized medicine has also accelerated interest in mRNA-based cancer vaccines, where patients receive customized treatments targeting specific tumor antigens. Additionally, the growing adoption of AI-driven drug discovery is streamlining mRNA sequence design, optimizing formulations, and reducing development timelines. The increasing demand for decentralized vaccine production and regional manufacturing hubs has spurred investments in mRNA production facilities, further supporting market expansion. The continued refinement of lipid nanoparticles and alternative delivery systems has enhanced the efficacy and safety of mRNA drugs, driving broader clinical adoption. Furthermore, government initiatives focused on pandemic preparedness and biopharmaceutical innovation are providing funding and regulatory support for mRNA therapeutics. As new indications emerge and manufacturing capabilities improve, the mRNA therapeutics market is poised for sustained growth, revolutionizing the treatment landscape for numerous diseases and positioning mRNA technology as a cornerstone of next-generation medicine.

SCOPE OF STUDY:

The report analyzes the mRNA Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Prophylactic Products, Therapeutic Products); Application (Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application, Other Applications); End-Use (Hospitals & Clinics End-Use, Research Organizations End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

  • Abogen Biosciences
  • Alnylam Pharmaceuticals
  • Anima Biotech
  • Arcturus Therapeutics Holdings Inc.
  • BioNTech SE
  • Comanche Biopharma
  • CureVac N.V.
  • eTheRNA Immunotherapies NV
  • Ethris GmbH
  • EXACIS Biotherapeutics
  • Gritstone bio, Inc.
  • HC Bioscience
  • Inflammatix, Inc.
  • Ionis Pharmaceuticals
  • Moderna, Inc.
  • Nutcracker Therapeutics
  • Orna Therapeutics
  • ReCode Therapeutics
  • Strand Therapeutics
  • Translate Bio (acquired by Sanofi)

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Show more
Product Code: MCP32236

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • mRNA Therapeutics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Investment in mRNA Technology for Therapeutic Development Drives Market Growth
    • Surge in Global Demand for mRNA-Based Vaccines Expands Market Opportunity for mRNA Therapeutics
    • Accelerated Research and Development in mRNA-Based Cancer Therapies Expands Market Horizons
    • Regulatory Support and Fast-Track Approvals for mRNA Therapies Strengthen Market Confidence and Adoption
    • Technological Advancements in mRNA Delivery Systems Propel Growth in Therapeutic Applications
    • Rising Consumer Demand for Personalized Medicine Drives Adoption of mRNA Therapeutics in Tailored Treatment Plans
    • The Emergence of mRNA-based Infectious Disease Treatments Spells Long-term Growth for the Therapeutics Market
    • Increasing Use of mRNA Vaccines in Global Immunization Campaigns Accelerates Market Adoption
    • The Shift Toward Preventive Healthcare and Proactive Disease Management Boosts Demand for mRNA Therapeutics
    • Growing Integration of mRNA Technology into Cancer Immunotherapies Expands Market Opportunity
    • Increasing Collaborations Between Biopharma Companies and Research Institutions Fuel mRNA Therapeutics Innovation
    • The Global COVID-19 Pandemic Drives Significant Investment and Infrastructure Development for mRNA Therapeutics
    • Expansion of Clinical Trials for mRNA Therapeutics in Rare and Genetic Diseases Spurs Market Potential
    • Rising Focus on the Safety and Efficacy of mRNA-based Therapies Strengthens Consumer Confidence and Adoption
    • The Growing Role of Artificial Intelligence and Machine Learning in mRNA Therapeutics Development Drives Innovation
    • Expansion of Manufacturing Capabilities for mRNA-based Drugs Increases Market Accessibility and Scalability
    • Increasing Global Health Initiatives and Public-Private Partnerships Accelerates Demand for mRNA Therapeutics
    • The Rise of mRNA-based Protein Replacement Therapies Strengthens Market Demand for mRNA in Genetic Disorders
    • Regulatory and Ethical Issues Surrounding mRNA Technology Drive Innovation in Safety Protocols and Guidelines
    • Increasing Interest in mRNA as a Platform for Targeted Therapies Expands Addressable Market Opportunity for Therapeutic Products
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World mRNA Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for mRNA Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for mRNA Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Prophylactic Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Prophylactic Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Therapeutic Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Therapeutic Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Hospitals & Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Research Organizations End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Research Organizations End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Infectious Diseases Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Infectious Diseases Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Oncology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Oncology Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Rare Genetic Diseases Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Rare Genetic Diseases Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Respiratory Diseases Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World 6-Year Perspective for Respiratory Diseases Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 23: World 6-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • mRNA Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 24: USA Recent Past, Current & Future Analysis for mRNA Therapeutics by Type - Prophylactic Products and Therapeutic Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 25: USA 6-Year Perspective for mRNA Therapeutics by Type - Percentage Breakdown of Value Sales for Prophylactic Products and Therapeutic Products for the Years 2025 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for mRNA Therapeutics by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA 6-Year Perspective for mRNA Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use for the Years 2025 & 2030
    • TABLE 28: USA Recent Past, Current & Future Analysis for mRNA Therapeutics by Application - Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 29: USA 6-Year Perspective for mRNA Therapeutics by Application - Percentage Breakdown of Value Sales for Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications for the Years 2025 & 2030
  • CANADA
    • TABLE 30: Canada Recent Past, Current & Future Analysis for mRNA Therapeutics by Type - Prophylactic Products and Therapeutic Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 31: Canada 6-Year Perspective for mRNA Therapeutics by Type - Percentage Breakdown of Value Sales for Prophylactic Products and Therapeutic Products for the Years 2025 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for mRNA Therapeutics by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada 6-Year Perspective for mRNA Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use for the Years 2025 & 2030
    • TABLE 34: Canada Recent Past, Current & Future Analysis for mRNA Therapeutics by Application - Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 35: Canada 6-Year Perspective for mRNA Therapeutics by Application - Percentage Breakdown of Value Sales for Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications for the Years 2025 & 2030
  • JAPAN
    • mRNA Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 36: Japan Recent Past, Current & Future Analysis for mRNA Therapeutics by Type - Prophylactic Products and Therapeutic Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 37: Japan 6-Year Perspective for mRNA Therapeutics by Type - Percentage Breakdown of Value Sales for Prophylactic Products and Therapeutic Products for the Years 2025 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for mRNA Therapeutics by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan 6-Year Perspective for mRNA Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use for the Years 2025 & 2030
    • TABLE 40: Japan Recent Past, Current & Future Analysis for mRNA Therapeutics by Application - Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Japan 6-Year Perspective for mRNA Therapeutics by Application - Percentage Breakdown of Value Sales for Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications for the Years 2025 & 2030
  • CHINA
    • mRNA Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 42: China Recent Past, Current & Future Analysis for mRNA Therapeutics by Type - Prophylactic Products and Therapeutic Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 43: China 6-Year Perspective for mRNA Therapeutics by Type - Percentage Breakdown of Value Sales for Prophylactic Products and Therapeutic Products for the Years 2025 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for mRNA Therapeutics by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China 6-Year Perspective for mRNA Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use for the Years 2025 & 2030
    • TABLE 46: China Recent Past, Current & Future Analysis for mRNA Therapeutics by Application - Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 47: China 6-Year Perspective for mRNA Therapeutics by Application - Percentage Breakdown of Value Sales for Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications for the Years 2025 & 2030
  • EUROPE
    • mRNA Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 48: Europe Recent Past, Current & Future Analysis for mRNA Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 49: Europe 6-Year Perspective for mRNA Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for mRNA Therapeutics by Type - Prophylactic Products and Therapeutic Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe 6-Year Perspective for mRNA Therapeutics by Type - Percentage Breakdown of Value Sales for Prophylactic Products and Therapeutic Products for the Years 2025 & 2030
    • TABLE 52: Europe Recent Past, Current & Future Analysis for mRNA Therapeutics by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Europe 6-Year Perspective for mRNA Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use for the Years 2025 & 2030
    • TABLE 54: Europe Recent Past, Current & Future Analysis for mRNA Therapeutics by Application - Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 55: Europe 6-Year Perspective for mRNA Therapeutics by Application - Percentage Breakdown of Value Sales for Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications for the Years 2025 & 2030
  • FRANCE
    • mRNA Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for mRNA Therapeutics by Type - Prophylactic Products and Therapeutic Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France 6-Year Perspective for mRNA Therapeutics by Type - Percentage Breakdown of Value Sales for Prophylactic Products and Therapeutic Products for the Years 2025 & 2030
    • TABLE 58: France Recent Past, Current & Future Analysis for mRNA Therapeutics by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 59: France 6-Year Perspective for mRNA Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use for the Years 2025 & 2030
    • TABLE 60: France Recent Past, Current & Future Analysis for mRNA Therapeutics by Application - Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 61: France 6-Year Perspective for mRNA Therapeutics by Application - Percentage Breakdown of Value Sales for Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications for the Years 2025 & 2030
  • GERMANY
    • mRNA Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for mRNA Therapeutics by Type - Prophylactic Products and Therapeutic Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany 6-Year Perspective for mRNA Therapeutics by Type - Percentage Breakdown of Value Sales for Prophylactic Products and Therapeutic Products for the Years 2025 & 2030
    • TABLE 64: Germany Recent Past, Current & Future Analysis for mRNA Therapeutics by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 65: Germany 6-Year Perspective for mRNA Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use for the Years 2025 & 2030
    • TABLE 66: Germany Recent Past, Current & Future Analysis for mRNA Therapeutics by Application - Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Germany 6-Year Perspective for mRNA Therapeutics by Application - Percentage Breakdown of Value Sales for Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications for the Years 2025 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for mRNA Therapeutics by Type - Prophylactic Products and Therapeutic Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy 6-Year Perspective for mRNA Therapeutics by Type - Percentage Breakdown of Value Sales for Prophylactic Products and Therapeutic Products for the Years 2025 & 2030
    • TABLE 70: Italy Recent Past, Current & Future Analysis for mRNA Therapeutics by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 71: Italy 6-Year Perspective for mRNA Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use for the Years 2025 & 2030
    • TABLE 72: Italy Recent Past, Current & Future Analysis for mRNA Therapeutics by Application - Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 73: Italy 6-Year Perspective for mRNA Therapeutics by Application - Percentage Breakdown of Value Sales for Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications for the Years 2025 & 2030
  • UNITED KINGDOM
    • mRNA Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for mRNA Therapeutics by Type - Prophylactic Products and Therapeutic Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK 6-Year Perspective for mRNA Therapeutics by Type - Percentage Breakdown of Value Sales for Prophylactic Products and Therapeutic Products for the Years 2025 & 2030
    • TABLE 76: UK Recent Past, Current & Future Analysis for mRNA Therapeutics by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 77: UK 6-Year Perspective for mRNA Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use for the Years 2025 & 2030
    • TABLE 78: UK Recent Past, Current & Future Analysis for mRNA Therapeutics by Application - Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 79: UK 6-Year Perspective for mRNA Therapeutics by Application - Percentage Breakdown of Value Sales for Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications for the Years 2025 & 2030
  • SPAIN
    • TABLE 80: Spain Recent Past, Current & Future Analysis for mRNA Therapeutics by Type - Prophylactic Products and Therapeutic Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain 6-Year Perspective for mRNA Therapeutics by Type - Percentage Breakdown of Value Sales for Prophylactic Products and Therapeutic Products for the Years 2025 & 2030
    • TABLE 82: Spain Recent Past, Current & Future Analysis for mRNA Therapeutics by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 83: Spain 6-Year Perspective for mRNA Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use for the Years 2025 & 2030
    • TABLE 84: Spain Recent Past, Current & Future Analysis for mRNA Therapeutics by Application - Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Spain 6-Year Perspective for mRNA Therapeutics by Application - Percentage Breakdown of Value Sales for Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications for the Years 2025 & 2030
  • RUSSIA
    • TABLE 86: Russia Recent Past, Current & Future Analysis for mRNA Therapeutics by Type - Prophylactic Products and Therapeutic Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia 6-Year Perspective for mRNA Therapeutics by Type - Percentage Breakdown of Value Sales for Prophylactic Products and Therapeutic Products for the Years 2025 & 2030
    • TABLE 88: Russia Recent Past, Current & Future Analysis for mRNA Therapeutics by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Russia 6-Year Perspective for mRNA Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use for the Years 2025 & 2030
    • TABLE 90: Russia Recent Past, Current & Future Analysis for mRNA Therapeutics by Application - Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Russia 6-Year Perspective for mRNA Therapeutics by Application - Percentage Breakdown of Value Sales for Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for mRNA Therapeutics by Type - Prophylactic Products and Therapeutic Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe 6-Year Perspective for mRNA Therapeutics by Type - Percentage Breakdown of Value Sales for Prophylactic Products and Therapeutic Products for the Years 2025 & 2030
    • TABLE 94: Rest of Europe Recent Past, Current & Future Analysis for mRNA Therapeutics by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Rest of Europe 6-Year Perspective for mRNA Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use for the Years 2025 & 2030
    • TABLE 96: Rest of Europe Recent Past, Current & Future Analysis for mRNA Therapeutics by Application - Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 97: Rest of Europe 6-Year Perspective for mRNA Therapeutics by Application - Percentage Breakdown of Value Sales for Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications for the Years 2025 & 2030
  • ASIA-PACIFIC
    • mRNA Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for mRNA Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific 6-Year Perspective for mRNA Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2025 & 2030
    • TABLE 100: Asia-Pacific Recent Past, Current & Future Analysis for mRNA Therapeutics by Type - Prophylactic Products and Therapeutic Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 101: Asia-Pacific 6-Year Perspective for mRNA Therapeutics by Type - Percentage Breakdown of Value Sales for Prophylactic Products and Therapeutic Products for the Years 2025 & 2030
    • TABLE 102: Asia-Pacific Recent Past, Current & Future Analysis for mRNA Therapeutics by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 103: Asia-Pacific 6-Year Perspective for mRNA Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use for the Years 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for mRNA Therapeutics by Application - Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific 6-Year Perspective for mRNA Therapeutics by Application - Percentage Breakdown of Value Sales for Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications for the Years 2025 & 2030
  • AUSTRALIA
    • mRNA Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 106: Australia Recent Past, Current & Future Analysis for mRNA Therapeutics by Type - Prophylactic Products and Therapeutic Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 107: Australia 6-Year Perspective for mRNA Therapeutics by Type - Percentage Breakdown of Value Sales for Prophylactic Products and Therapeutic Products for the Years 2025 & 2030
    • TABLE 108: Australia Recent Past, Current & Future Analysis for mRNA Therapeutics by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 109: Australia 6-Year Perspective for mRNA Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use for the Years 2025 & 2030
    • TABLE 110: Australia Recent Past, Current & Future Analysis for mRNA Therapeutics by Application - Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia 6-Year Perspective for mRNA Therapeutics by Application - Percentage Breakdown of Value Sales for Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications for the Years 2025 & 2030
  • INDIA
    • mRNA Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 112: India Recent Past, Current & Future Analysis for mRNA Therapeutics by Type - Prophylactic Products and Therapeutic Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 113: India 6-Year Perspective for mRNA Therapeutics by Type - Percentage Breakdown of Value Sales for Prophylactic Products and Therapeutic Products for the Years 2025 & 2030
    • TABLE 114: India Recent Past, Current & Future Analysis for mRNA Therapeutics by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 115: India 6-Year Perspective for mRNA Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use for the Years 2025 & 2030
    • TABLE 116: India Recent Past, Current & Future Analysis for mRNA Therapeutics by Application - Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India 6-Year Perspective for mRNA Therapeutics by Application - Percentage Breakdown of Value Sales for Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications for the Years 2025 & 2030
  • SOUTH KOREA
    • TABLE 118: South Korea Recent Past, Current & Future Analysis for mRNA Therapeutics by Type - Prophylactic Products and Therapeutic Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 119: South Korea 6-Year Perspective for mRNA Therapeutics by Type - Percentage Breakdown of Value Sales for Prophylactic Products and Therapeutic Products for the Years 2025 & 2030
    • TABLE 120: South Korea Recent Past, Current & Future Analysis for mRNA Therapeutics by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 121: South Korea 6-Year Perspective for mRNA Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use for the Years 2025 & 2030
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for mRNA Therapeutics by Application - Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea 6-Year Perspective for mRNA Therapeutics by Application - Percentage Breakdown of Value Sales for Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications for the Years 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 124: Rest of Asia-Pacific Recent Past, Current & Future Analysis for mRNA Therapeutics by Type - Prophylactic Products and Therapeutic Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 125: Rest of Asia-Pacific 6-Year Perspective for mRNA Therapeutics by Type - Percentage Breakdown of Value Sales for Prophylactic Products and Therapeutic Products for the Years 2025 & 2030
    • TABLE 126: Rest of Asia-Pacific Recent Past, Current & Future Analysis for mRNA Therapeutics by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 6-Year Perspective for mRNA Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use for the Years 2025 & 2030
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for mRNA Therapeutics by Application - Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific 6-Year Perspective for mRNA Therapeutics by Application - Percentage Breakdown of Value Sales for Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications for the Years 2025 & 2030
  • LATIN AMERICA
    • mRNA Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 130: Latin America Recent Past, Current & Future Analysis for mRNA Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 131: Latin America 6-Year Perspective for mRNA Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2025 & 2030
    • TABLE 132: Latin America Recent Past, Current & Future Analysis for mRNA Therapeutics by Type - Prophylactic Products and Therapeutic Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 133: Latin America 6-Year Perspective for mRNA Therapeutics by Type - Percentage Breakdown of Value Sales for Prophylactic Products and Therapeutic Products for the Years 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for mRNA Therapeutics by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America 6-Year Perspective for mRNA Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use for the Years 2025 & 2030
    • TABLE 136: Latin America Recent Past, Current & Future Analysis for mRNA Therapeutics by Application - Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 137: Latin America 6-Year Perspective for mRNA Therapeutics by Application - Percentage Breakdown of Value Sales for Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications for the Years 2025 & 2030
  • ARGENTINA
    • TABLE 138: Argentina Recent Past, Current & Future Analysis for mRNA Therapeutics by Type - Prophylactic Products and Therapeutic Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 139: Argentina 6-Year Perspective for mRNA Therapeutics by Type - Percentage Breakdown of Value Sales for Prophylactic Products and Therapeutic Products for the Years 2025 & 2030
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for mRNA Therapeutics by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina 6-Year Perspective for mRNA Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use for the Years 2025 & 2030
    • TABLE 142: Argentina Recent Past, Current & Future Analysis for mRNA Therapeutics by Application - Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 143: Argentina 6-Year Perspective for mRNA Therapeutics by Application - Percentage Breakdown of Value Sales for Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications for the Years 2025 & 2030
  • BRAZIL
    • TABLE 144: Brazil Recent Past, Current & Future Analysis for mRNA Therapeutics by Type - Prophylactic Products and Therapeutic Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 145: Brazil 6-Year Perspective for mRNA Therapeutics by Type - Percentage Breakdown of Value Sales for Prophylactic Products and Therapeutic Products for the Years 2025 & 2030
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for mRNA Therapeutics by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil 6-Year Perspective for mRNA Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use for the Years 2025 & 2030
    • TABLE 148: Brazil Recent Past, Current & Future Analysis for mRNA Therapeutics by Application - Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 149: Brazil 6-Year Perspective for mRNA Therapeutics by Application - Percentage Breakdown of Value Sales for Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications for the Years 2025 & 2030
  • MEXICO
    • TABLE 150: Mexico Recent Past, Current & Future Analysis for mRNA Therapeutics by Type - Prophylactic Products and Therapeutic Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 151: Mexico 6-Year Perspective for mRNA Therapeutics by Type - Percentage Breakdown of Value Sales for Prophylactic Products and Therapeutic Products for the Years 2025 & 2030
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for mRNA Therapeutics by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico 6-Year Perspective for mRNA Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use for the Years 2025 & 2030
    • TABLE 154: Mexico Recent Past, Current & Future Analysis for mRNA Therapeutics by Application - Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 155: Mexico 6-Year Perspective for mRNA Therapeutics by Application - Percentage Breakdown of Value Sales for Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications for the Years 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 156: Rest of Latin America Recent Past, Current & Future Analysis for mRNA Therapeutics by Type - Prophylactic Products and Therapeutic Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 157: Rest of Latin America 6-Year Perspective for mRNA Therapeutics by Type - Percentage Breakdown of Value Sales for Prophylactic Products and Therapeutic Products for the Years 2025 & 2030
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for mRNA Therapeutics by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America 6-Year Perspective for mRNA Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use for the Years 2025 & 2030
    • TABLE 160: Rest of Latin America Recent Past, Current & Future Analysis for mRNA Therapeutics by Application - Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 161: Rest of Latin America 6-Year Perspective for mRNA Therapeutics by Application - Percentage Breakdown of Value Sales for Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications for the Years 2025 & 2030
  • MIDDLE EAST
    • mRNA Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 162: Middle East Recent Past, Current & Future Analysis for mRNA Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 163: Middle East 6-Year Perspective for mRNA Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2025 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for mRNA Therapeutics by Type - Prophylactic Products and Therapeutic Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East 6-Year Perspective for mRNA Therapeutics by Type - Percentage Breakdown of Value Sales for Prophylactic Products and Therapeutic Products for the Years 2025 & 2030
    • TABLE 166: Middle East Recent Past, Current & Future Analysis for mRNA Therapeutics by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 167: Middle East 6-Year Perspective for mRNA Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use for the Years 2025 & 2030
    • TABLE 168: Middle East Recent Past, Current & Future Analysis for mRNA Therapeutics by Application - Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 169: Middle East 6-Year Perspective for mRNA Therapeutics by Application - Percentage Breakdown of Value Sales for Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications for the Years 2025 & 2030
  • IRAN
    • TABLE 170: Iran Recent Past, Current & Future Analysis for mRNA Therapeutics by Type - Prophylactic Products and Therapeutic Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Iran 6-Year Perspective for mRNA Therapeutics by Type - Percentage Breakdown of Value Sales for Prophylactic Products and Therapeutic Products for the Years 2025 & 2030
    • TABLE 172: Iran Recent Past, Current & Future Analysis for mRNA Therapeutics by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 173: Iran 6-Year Perspective for mRNA Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use for the Years 2025 & 2030
    • TABLE 174: Iran Recent Past, Current & Future Analysis for mRNA Therapeutics by Application - Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 175: Iran 6-Year Perspective for mRNA Therapeutics by Application - Percentage Breakdown of Value Sales for Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications for the Years 2025 & 2030
  • ISRAEL
    • TABLE 176: Israel Recent Past, Current & Future Analysis for mRNA Therapeutics by Type - Prophylactic Products and Therapeutic Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Israel 6-Year Perspective for mRNA Therapeutics by Type - Percentage Breakdown of Value Sales for Prophylactic Products and Therapeutic Products for the Years 2025 & 2030
    • TABLE 178: Israel Recent Past, Current & Future Analysis for mRNA Therapeutics by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 179: Israel 6-Year Perspective for mRNA Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use for the Years 2025 & 2030
    • TABLE 180: Israel Recent Past, Current & Future Analysis for mRNA Therapeutics by Application - Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 181: Israel 6-Year Perspective for mRNA Therapeutics by Application - Percentage Breakdown of Value Sales for Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications for the Years 2025 & 2030
  • SAUDI ARABIA
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for mRNA Therapeutics by Type - Prophylactic Products and Therapeutic Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia 6-Year Perspective for mRNA Therapeutics by Type - Percentage Breakdown of Value Sales for Prophylactic Products and Therapeutic Products for the Years 2025 & 2030
    • TABLE 184: Saudi Arabia Recent Past, Current & Future Analysis for mRNA Therapeutics by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 185: Saudi Arabia 6-Year Perspective for mRNA Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use for the Years 2025 & 2030
    • TABLE 186: Saudi Arabia Recent Past, Current & Future Analysis for mRNA Therapeutics by Application - Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 187: Saudi Arabia 6-Year Perspective for mRNA Therapeutics by Application - Percentage Breakdown of Value Sales for Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications for the Years 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 188: UAE Recent Past, Current & Future Analysis for mRNA Therapeutics by Type - Prophylactic Products and Therapeutic Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: UAE 6-Year Perspective for mRNA Therapeutics by Type - Percentage Breakdown of Value Sales for Prophylactic Products and Therapeutic Products for the Years 2025 & 2030
    • TABLE 190: UAE Recent Past, Current & Future Analysis for mRNA Therapeutics by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 191: UAE 6-Year Perspective for mRNA Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use for the Years 2025 & 2030
    • TABLE 192: UAE Recent Past, Current & Future Analysis for mRNA Therapeutics by Application - Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 193: UAE 6-Year Perspective for mRNA Therapeutics by Application - Percentage Breakdown of Value Sales for Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications for the Years 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for mRNA Therapeutics by Type - Prophylactic Products and Therapeutic Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East 6-Year Perspective for mRNA Therapeutics by Type - Percentage Breakdown of Value Sales for Prophylactic Products and Therapeutic Products for the Years 2025 & 2030
    • TABLE 196: Rest of Middle East Recent Past, Current & Future Analysis for mRNA Therapeutics by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 197: Rest of Middle East 6-Year Perspective for mRNA Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use for the Years 2025 & 2030
    • TABLE 198: Rest of Middle East Recent Past, Current & Future Analysis for mRNA Therapeutics by Application - Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 199: Rest of Middle East 6-Year Perspective for mRNA Therapeutics by Application - Percentage Breakdown of Value Sales for Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications for the Years 2025 & 2030
  • AFRICA
    • mRNA Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 200: Africa Recent Past, Current & Future Analysis for mRNA Therapeutics by Type - Prophylactic Products and Therapeutic Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Africa 6-Year Perspective for mRNA Therapeutics by Type - Percentage Breakdown of Value Sales for Prophylactic Products and Therapeutic Products for the Years 2025 & 2030
    • TABLE 202: Africa Recent Past, Current & Future Analysis for mRNA Therapeutics by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 203: Africa 6-Year Perspective for mRNA Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use for the Years 2025 & 2030
    • TABLE 204: Africa Recent Past, Current & Future Analysis for mRNA Therapeutics by Application - Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 205: Africa 6-Year Perspective for mRNA Therapeutics by Application - Percentage Breakdown of Value Sales for Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications for the Years 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!